Stem cells are emerging as a powerful biomedical tool, and significant applications in drug/toxin screening, disease modeling, and clinical cell therapy are on the horizon. Recent studies have pushed stem cells closer to biomedical applications by improving stem cell biomanufacturing processes, including cell expansion, differentiation and tissue morphogenesis. However, the need for costly and poorly defined biological supplements such as recombinant growth factors (GFs) remains a prohibitive challenge. GF supplements can represent more than half of the cost of stem cell biomanufacturing processes in emerging applications, and existing processes remain dependent on complex, poorly defined GF-binding matrices such as Matrigel. Remarkably, while the current paradigm involves bombarding stem cells with concentrated GF- containing supplements, many of the relevant GFs in stem cell biomanufacturing are already routinely produced by the stem cells themselves. There is an opportunity to shift the current paradigm by capturing cell- secreted GFs, leading to less costly and more well-defined stem cell biomanufacturing. Context: Our initial funding period (7/1/2009-6/30/2014) established new mechanisms for specific GF sequestering, and produced 33 manuscripts, 8 patent applications, and 5 technology licenses to industry partners. We discovered that biomaterials engineered with biomimetic peptides could regulate specific GF signaling in adult cell culture. During the next funding period we will use our defined GF sequestering concept to circumvent critical barriers in biomedical applications of stem cells. A central, provocative question driving the next funding period is: can engineered biomaterials control GF-dependent stem cell expansion, differentiation, and morphogenesis without delivering any GFs? Specific Aims:
Specific Aim 1 will use biomaterials to sequester cell-secreted GFs and amplify human mesenchymal stem cell expansion and differentiation.
Specific Aim 2 will use biomaterials to locally regulate specific GF activity in human induced pluripotent stem cell culture, and thereby enhance production of stem cell-derived endothelial cells.
Specific Aim 3 will develop biomaterials that can selectively control paracrine signaling during vascular morphogenesis in vitro and in vivo. Innovation: Our proposed studies will establish synthetic biomaterials as defined mediators of endogenous, recombinant, and paracrine GF signaling. Significance: Our proposed studies will mitigate the need for expensive and complex biological supplements that currently hinder biomedical applications of stem cells. The resulting approach will be transformative, as GF supplements represent the primary driving force for increased cost and regulatory burden in stem cell applications.
Stem cells are emerging as a powerful biomedical tool, and significant applications in drug discovery, environmental toxin screening, disease modeling, and clinical cell therapy are on the horizon. Recent studies have pushed stem cells closer to these biomedical applications by improving stem cell 'biomanufacturing' processes, such as stem cell expansion, differentiation and tissue formation. Growth factors, which are specialized proteins that control how quickly stem cells grow and what they ultimately become, are among the most powerful tools for stem cell biomanufacturing. However, growth factors are also prohibitively expensive and too complex for many stem cell applications. The critical importance of growth factors, juxtaposed with the cost and regulatory hurdles they present, puts the field at an impasse. Bioengineers and physicians simply cannot continue to rely on growth factor supplements to do the heavy lifting in stem cell biomanufacturing processes. Fortunately, the growth factors that are most critical to stem cell growth and tissue formation are already being continuously produced by the stem cells themselves. They are simply not 'harnessed' in a way that allows them to influence the cells. We propose to develop biomaterials that can mitigate the need for growth factor supplements by harnessing the effects of cell-secreted growth factors. The result will be a new class of biomaterials that can accelerate stem cell growth and control what stem cells will ultimately become, even without the help of expensive and complex growth factor supplements. The approach can, in principle, be generalized to any growth factor and any stem cell type of interest. We anticipate that the proposed approach will be transformative, as it will address the most substantial cost and regulatory barriers in biomedical applications of stem cells.
| Adamski, Michal; Fontana, Gianluca; Gershlak, Joshua R et al. (2018) Two Methods for Decellularization of Plant Tissues for Tissue Engineering Applications. J Vis Exp : |
| Lei, Jennifer; Murphy, William L; Temenoff, Johnna S (2018) Combination of Heparin Binding Peptide and Heparin Cell Surface Coatings for Mesenchymal Stem Cell Spheroid Assembly. Bioconjug Chem 29:878-884 |
| Piscopo, Nicole J; Mueller, Katherine P; Das, Amritava et al. (2018) Bioengineering Solutions for Manufacturing Challenges in CAR T Cells. Biotechnol J 13: |
| Zhu, Yichen; Takayama, Toshio; Wang, Bowen et al. (2017) Restenosis Inhibition and Re-differentiation of TGF?/Smad3-activated Smooth Muscle Cells by Resveratrol. Sci Rep 7:41916 |
| Parlato, Matthew; Molenda, James; Murphy, William L (2017) Specific recruitment of circulating angiogenic cells using biomaterials as filters. Acta Biomater 56:65-79 |
| Regier, Mary C; Montanez-Sauri, Sara I; Schwartz, Michael P et al. (2017) The Influence of Biomaterials on Cytokine Production in 3D Cultures. Biomacromolecules 18:709-718 |
| Zhang, Jue; Schwartz, Michael P; Hou, Zhonggang et al. (2017) A Genome-wide Analysis of Human Pluripotent Stem Cell-Derived Endothelial Cells in 2D or 3D Culture. Stem Cell Reports 8:907-918 |
| Dias, Andrew D; Elicson, Jonathan M; Murphy, William L (2017) Microcarriers with Synthetic Hydrogel Surfaces for Stem Cell Expansion. Adv Healthc Mater 6: |
| Barry, Christopher; Schmitz, Matthew T; Propson, Nicholas E et al. (2017) Uniform neural tissue models produced on synthetic hydrogels using standard culture techniques. Exp Biol Med (Maywood) 242:1679-1689 |
| Fontana, Gianluca; Gershlak, Joshua; Adamski, Michal et al. (2017) Biofunctionalized Plants as Diverse Biomaterials for Human Cell Culture. Adv Healthc Mater 6: |
Showing the most recent 10 out of 57 publications
